David Isenberg
About
In The Last Decade
David Isenberg
945 papers receiving 44.5k citations
Hit Papers
Peers
Comparison fields: 5 of 166
- Rheumatology 27.9k
- Immunology 22.8k
- Radiology, Nuclear Medicine and Imaging 11.6k
- Molecular Biology 6.0k
- Pathology and Forensic Medicine 5.4k
Countries citing papers authored by David Isenberg
This map shows the geographic impact of David Isenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Isenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Isenberg more than expected).
Fields of papers citing papers by David Isenberg
This network shows the impact of papers produced by David Isenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Isenberg. The network helps show where David Isenberg may publish in the future.
Co-authorship network of co-authors of David Isenberg
This figure shows the co-authorship network connecting the top 25 collaborators of David Isenberg. A scholar is included among the top collaborators of David Isenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Isenberg. David Isenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 0 | |
| 5 | 2 | |
| 6 | Biologics in rheumatology: New developments, clinical uses and health implication | 1 |
| 7 | Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register | 1 |
| 8 | CD19 + CD24 hi CD38 hi B Cells Maintain Regulatory T Cells While Limiting T H 1 and T H 17 Differentiation breakdown → | 539 |
| 9 | 1 | |
| 10 | Nonrenal Disease Activity Following Mycophenolate Mofetil or Intravenous Cyclophosphamide as Induction Treatment for Lupus Nephritis | 1 |
| 11 | The UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC): In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype rather than by myositis sub type. | 2 |
| 12 | Inter-rater reliability and validity of two disease activity assessment tools in patients with idiopathic inflammatory myositis (IIM) | 1 |
| 13 | B lymphocyte depletion in the treatment of systemic lupus erythematosus. | 10 |
| 14 | TREATMENT OF REFRACTORY LUPUS NEPHRITIS WITH B LYMPHOCYTE DEPLETION | 8 |
| 15 | Systemic lupus erythematosus measures. | 3 |
| 16 | 69 | |
| 17 | Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. | 67 |
| 18 | Genetic structural and functional properties of a human IgG anti-DNA autoantibody | 1 |
| 19 | 9 | |
| 20 | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.